PERSANTINE TAB 75MG TABLET

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

DIPYRIDAMOLE

제공처:

BOEHRINGER INGELHEIM (CANADA) LTD LTEE

ATC 코드:

B01AC07

INN (국제 이름):

DIPYRIDAMOLE

복용량:

75MG

약제 형태:

TABLET

구성:

DIPYRIDAMOLE 75MG

관리 경로:

ORAL

패키지 단위:

100

처방전 유형:

Prescription

치료 영역:

MISCELLANEOUS VASODILATATING AGENTS

제품 요약:

Active ingredient group (AIG) number: 0106621003; AHFS:

승인 상태:

CANCELLED POST MARKET

승인 날짜:

2010-06-28

제품 특성 요약

_ _
_Product Monograph _
_Page 1 of 22 _
PRODUCT MONOGRAPH
Pr
PERSANTINE
®
Dipyridamole Tablets
Dipyridamole for Injection
50 mg and 75 mg tablets
5 mg/mL injectable ampoules
Coronary Vasodilator
Inhibitor of Platelet Adhesion and Aggregation
Boehringer Ingelheim Canada Ltd.
5180 South Service Road
Burlington, ON L7L 5H4
Date of Preparation:
March 15, 1995
Date of Revision:
May 20, 2005
Submission Control No: 092334
BI BPI number: 0248-02 (tablets), 0150-04 (ampoules)
_ _
_Product Monograph _
_Page 2 of 22_
Table of Contents
[To update, right-click anywhere in the Table of Contents and select
“Update Field”, “Update
entire table”, click OK.]
PART I: HEALTH PROFESSIONAL
INFORMATION.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL
USE..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND
PRECAUTIONS..................................................................................4
ADVERSE
REACTIONS....................................................................................................5
DRUG INTERACTIONS
....................................................................................................8
DOSAGE AND
ADMINISTRATION................................................................................9
OVERDOSAGE
..................................................................................................................9
ACTION AND CLINICAL PHARMACOLOGY
............................................................10
STORAGE AND
STABILITY..........................................................................................11
SPECIAL HANDLING INSTRUCTIONS
.......................................................................11
DOSAGE FORMS, COMPOSITION AND PACKAGING
...........................